Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

MDLinxALZ-801 Trial Results Announced: A Breakthrough in Alzheimer’s Treatment?

On September 20, 2022, Alzheon Inc. announced promising results from its phase 2 trial of oral ALZ-801 (valiltramiprosate) in patients with early AD. The drug decreased p-tau181 levels, reduced brain atrophy, and improved cognitive skills in the trial.

Was this Essential useful?

More Essentials From

ACP Internist
Annals of Internal Medicine
British Medical Journal
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advisor
Consultant360
Dana-Farber Cancer Institute
Healthgrades for Professionals
MDLinx
Neurology Advisor
OBR Oncology
Oncology Learning Network
Psych Congress Network
Psychiatrist.com
The Epoch Times
The New England Journal of Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form